Mn Companies Vermogensbeheer B.V. lessened its holdings in Quest Diagnostics Integrated (NYSE:DGX – Free Report) by 2.3% through the third quarter, Holdings Channel stories. The agency owned 43,245 shares of the medical analysis firm’s inventory after promoting 1,000 shares through the quarter. Mn Companies Vermogensbeheer B.V.’s holdings in Quest Diagnostics have been price $6,714,000 on the finish of the newest reporting interval.
Different giant traders have additionally modified their holdings of the corporate. Rothschild Funding LLC acquired a brand new stake in Quest Diagnostics through the 2nd quarter valued at $26,000. Innealta Capital LLC acquired a brand new stake in shares of Quest Diagnostics through the second quarter valued at $31,000. Larson Monetary Group LLC lifted its holdings in Quest Diagnostics by 77.5% within the 2nd quarter. Larson Monetary Group LLC now owns 229 shares of the medical analysis firm’s inventory valued at $31,000 after buying a further 100 shares within the final quarter. TruNorth Capital Administration LLC acquired a brand new stake in shares of Quest Diagnostics through the 2nd quarter price about $33,000. Lastly, EdgeRock Capital LLC bought a brand new stake in shares of Quest Diagnostics through the second quarter price about $35,000. 88.06% of the inventory is presently owned by institutional traders and hedge funds.
Wall Avenue Analysts Forecast Development
Quite a few analysis analysts have weighed in on DGX shares. Piper Sandler elevated their value goal on Quest Diagnostics from $150.00 to $165.00 and gave the inventory a “impartial” score in a analysis notice on Monday, October twenty eighth. Robert W. Baird upgraded Quest Diagnostics from a “impartial” score to an “outperform” score and lifted their value goal for the corporate from $157.00 to $182.00 in a report on Wednesday, October twenty third. Mizuho elevated their value goal on shares of Quest Diagnostics from $160.00 to $174.00 and gave the inventory an “outperform” score in a report on Thursday, October twenty fourth. Truist Monetary boosted their goal value on shares of Quest Diagnostics from $158.00 to $165.00 and gave the corporate a “maintain” score in a report on Monday, October seventh. Lastly, Baird R W raised shares of Quest Diagnostics from a “maintain” score to a “strong-buy” score in a analysis notice on Wednesday, October twenty third. Eight funding analysts have rated the inventory with a maintain score, six have issued a purchase score and one has given a powerful purchase score to the corporate. In keeping with MarketBeat.com, the corporate has a median score of “Reasonable Purchase” and a consensus goal value of $164.58.
Learn Our Newest Evaluation on DGX
Insider Transactions at Quest Diagnostics
In different information, SVP Karthik Kuppusamy offered 1,775 shares of the inventory in a transaction dated Monday, October twenty eighth. The shares have been offered at a median value of $156.92, for a complete transaction of $278,533.00. Following the transaction, the senior vice chairman now owns 9,734 shares of the corporate’s inventory, valued at roughly $1,527,459.28. This commerce represents a 0.00 % lower of their possession of the inventory. The sale was disclosed in a doc filed with the SEC, which is accessible via this hyperlink. Insiders personal 0.79% of the corporate’s inventory.
Quest Diagnostics Inventory Up 0.7 %
Shares of Quest Diagnostics inventory opened at $155.20 on Thursday. The corporate has a debt-to-equity ratio of 0.83, a present ratio of 1.25 and a fast ratio of 1.17. Quest Diagnostics Integrated has a 1-year low of $123.04 and a 1-year excessive of $160.95. The enterprise has a 50-day transferring common of $153.48 and a 200-day transferring common of $146.33. The corporate has a market capitalization of $17.32 billion, a PE ratio of 20.86, a P/E/G ratio of two.68 and a beta of 0.89.
Quest Diagnostics (NYSE:DGX – Get Free Report) final posted its quarterly earnings knowledge on Tuesday, October twenty second. The medical analysis firm reported $2.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.26 by $0.04. The corporate had income of $2.49 billion for the quarter, in comparison with the consensus estimate of $2.43 billion. Quest Diagnostics had a return on fairness of 15.25% and a web margin of 8.82%. Quest Diagnostics’s income for the quarter was up 8.5% in comparison with the identical quarter final yr. Throughout the identical interval within the earlier yr, the enterprise earned $2.22 EPS. As a bunch, equities analysts forecast that Quest Diagnostics Integrated will put up 8.9 EPS for the present fiscal yr.
Quest Diagnostics Dividend Announcement
The enterprise additionally lately disclosed a quarterly dividend, which was paid on Monday, October twenty first. Shareholders of file on Friday, October 4th have been issued a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a yield of 1.93%. The ex-dividend date was Friday, October 4th. Quest Diagnostics’s dividend payout ratio is presently 40.32%.
Quest Diagnostics Firm Profile
Quest Diagnostics Integrated gives diagnostic testing and providers in the US and internationally. The corporate develops and delivers diagnostic info providers, similar to routine, non-routine and superior medical testing, anatomic pathology testing, and different diagnostic info providers.
Learn Extra
Wish to see what different hedge funds are holding DGX? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for Quest Diagnostics Integrated (NYSE:DGX – Free Report).
Obtain Information & Scores for Quest Diagnostics Day by day – Enter your e mail handle beneath to obtain a concise each day abstract of the most recent information and analysts’ scores for Quest Diagnostics and associated corporations with MarketBeat.com’s FREE each day e mail publication.
